A Chemotherapy-Photothermal synergistic system in bifunctional bone Scaffold: Tumor therapy and bone repair

Wu Di; Yan zuyun; Cijun Shuai; Yaping Wang; Youwen Deng; Wei Zhang; Li xin; Yan-Ying Xiao; Tan Wei

Materials & Design (Sep 2024)

A Chemotherapy-Photothermal synergistic system in bifunctional bone Scaffold: Tumor therapy and bone repair

Wu Di,
Yan zuyun,
Cijun Shuai,
Yaping Wang,
Youwen Deng,
Wei Zhang,
Li xin,
Yan-Ying Xiao,
Tan Wei

Affiliations

Wu Di: Department of Spine Surgery, The Third Xiangya Hospital of Central South University, Changsha 410013, China; Department of Pain Management, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Department of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Clinical Research Center for Pain Medicine in Hunan Province, Changsha, Hunan 410011, China; Hunan Province Center for Clinical Anesthesia and Anesthesiology, Research Institute of Central South University, Changsha, Hunan 410078, China
Yan zuyun: Department of Spine Surgery, The Third Xiangya Hospital of Central South University, Changsha 410013, China
Cijun Shuai: State Key Laboratory of Precision Manufacturing for Extreme Service Performance, College of Mechanical and Electrical Engineering, Central South University, Changsha, Hunan 410083, China
Yaping Wang: Department of Pain Management, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Department of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Clinical Research Center for Pain Medicine in Hunan Province, Changsha, Hunan 410011, China; Hunan Province Center for Clinical Anesthesia and Anesthesiology, Research Institute of Central South University, Changsha, Hunan 410078, China
Youwen Deng: Department of Spine Surgery, The Third Xiangya Hospital of Central South University, Changsha 410013, China
Wei Zhang: Department of Pain Management, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Department of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Clinical Research Center for Pain Medicine in Hunan Province, Changsha, Hunan 410011, China; Hunan Province Center for Clinical Anesthesia and Anesthesiology, Research Institute of Central South University, Changsha, Hunan 410078, China
Li xin: Department of Pain Management, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Department of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Clinical Research Center for Pain Medicine in Hunan Province, Changsha, Hunan 410011, China; Hunan Province Center for Clinical Anesthesia and Anesthesiology, Research Institute of Central South University, Changsha, Hunan 410078, China
Yan-Ying Xiao: Department of Pain Management, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Department of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Clinical Research Center for Pain Medicine in Hunan Province, Changsha, Hunan 410011, China; Hunan Province Center for Clinical Anesthesia and Anesthesiology, Research Institute of Central South University, Changsha, Hunan 410078, China; Corresponding authors.
Tan Wei: Department of Spine Surgery, The Third Xiangya Hospital of Central South University, Changsha 410013, China; Corresponding authors.

Journal volume & issue: Vol. 245
p. 113269

Abstract

Read online

Bone defect repair and tumor recurrence are the main challenges in the postoperative treatment of bone tumors. The incorporation of zoledronate (ZOL) into scaffolds presents a promising approach, attributed to its osteogenic and anti-tumor properties. However, there are still some unfavorable factors that make it difficult to eradicate tumor cells at the surgical site, including drug rapid release, the insufficient anti-tumor efficacy of ZOL and the multidrug resistance of chemotherapy. Herein, a novel nano drug delivery platform mesoporous silicon-coated graphene oxide (GO/MSN) and ZOL loaded nanoparticle (GO/MSN-ZOL) were developed. Then PLLA/ GO/MSN-ZOL scaffold that integrates photothermal therapy (PTT) and chemotherapy was fabricated using poly (L-lactic acid) as raw materials by selective laser sintering (SLS) technology. The GO not only imparted scaffold with photothermal properties for localized tumor cell ablation but also significantly enhanced its anti-tumor efficacy through synergistic effects in combination with chemotherapy. The mesoporous structure and large specific surface area of MSN contribute to the sustained release of ZOL. Additionally, GO could promote osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), which in combine with ZOL’s osteoclast inhibition, enhances the bone repair capacity. This study offers a straightforward and promising strategy for treating tumor-related bone defects.

Published in Materials & Design

ISSN: 0264-1275 (Print); 1873-4197 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Technology: Electrical engineering. Electronics. Nuclear engineering: Materials of engineering and construction. Mechanics of materials
Website: https://www.journals.elsevier.com/materials-and-design

About the journal

Abstract

Keywords